Posted inHematology-Oncology news
Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease
Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.